New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO. Need analyze transcript. Question asks: Does management indicate that economic terms of company's newest business — prices, rates, fees, spreads, contract sizes, durations, profitability at which most recent deals/orders/contracts/renewals are being struck — have stepped up meaningfully above company's own recent norm, and that improvement has only begun to flow into reported results because most business in reported numbers still written at older less favorable terms? Need use only transcript. Need identify if management says both halves. Transcript: Adaptive Biotechnologies. MRD clonoSEQ volumes, ASP. They mention ASP nearly $1,100 per test and expect it to continue to grow annually in mid-single digit. As finalize pricing agreements with non-contracted payers and improved collection performance. Also MRD pharma partnerships revenue growing. They guide 2023: MRD estimates include over 50% growth in clonoSEQ test volumes and continued ASP increase in mid-single digit range. Also milestones. They mention ASP growth trend towards $1700 per test over next few years. "We continue to invest in getting additional pricing agreements with non-contracted payers... improving collection performance... going after expanded coverage for new indications like DLBCL... expect ASP to grow steadily towards 1700 in next few years." This is about ASP increasing. Is that "new business terms" improved? They say ASP is nearly $1,100 per test and expect it to continue to grow annually in mid-single digit. This is achieved? They have pricing agreements. But is it "meaningfully above company's own recent norm"? Mid-single digit growth is not "meaningfully" step-up? Also "reported results still mostly reflect old terms"? They say "We anticipate ASP to continue to grow annually in mid-single digit" and "trend towards $1700 per test" over next few years. That implies future improvement, not already achieved? They say "ASP of 1100 ramped up faster than modeling" in analyst question. Management says "we've seen steady ASP growth over past couple years and anticipate that growth to continue in mid-single digit range over next two to three years and trend towards $1700." This is about pricing improving gradually.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...